CD40 and metastatic melanoma: Lipovaxin‐MM showed effective DC‐targeting property in vitro and well tolerance in metastatic melanoma patients, which makes it a promising platform for immunotherapeutic applications.89 In a study by Rosalia et al., protein antigens and two adjuvants (a TLR2 agonist and a TLR3 agonist) were encapsulated in PLGA NPs, with CD40 Ab coupling to the surface.136 The CD40 Ab specifically bound to CD40 that was abundantly expressed on DCs.